In vivo evaluation of an oral drug delivery system for peptides based on S-protected thiolated chitosan

被引:45
作者
Duennhaupt, Sarah [1 ]
Barthelmes, Jan [1 ]
Iqbal, Javed [1 ]
Perera, Glen [1 ]
Thurner, Clemens C. [2 ]
Friedl, Heike [2 ]
Bernkop-Schnuerch, Andreas [1 ]
机构
[1] Leopold Franzenz Univ Innsbruck, Inst Pharm, Dept Pharmaceut Technol, A-6020 Innsbruck, Austria
[2] ThioMatrix GmbH, Res Ctr Innsbruck, A-6020 Innsbruck, Austria
关键词
Oral peptide delivery; Antide; Thiolated chitosan; S-protected chitosan; Disulfide bond formation; Permeation enhancement; HORMONE ANTAGONIST ANTIDE; MUCOADHESIVE POLYMERS; ABSORPTION; GLUTATHIONE; MECHANISM; THIOMERS; AGENTS;
D O I
10.1016/j.jconrel.2012.04.020
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of the present study was the development and evaluation in vitro as well as in vivo of an oral delivery system based on a novel type of thiolated chitosan, so-called S-protected thiolated chitosan, for the peptide drug antide. The sulfhydryl ligand thioglycolic acid (TGA) was covalently attached to chitosan (CS) in the first step of modification. In the second step, these thiol groups of thiolated chitosan were protected by disulfide bond formation with the thiolated aromatic residue 6-mercaptonicotinamide (6-MNA). Absorptive transport studies of antide were evaluated ex vivo using rat intestinal mucosa. Matrix tablets of each polymer sample were prepared and their effect on the absorption of antide evaluated in vivo in male Sprague-Dawley rats. In addition, tablets were examined in terms of their disintegration, swelling and drug release behavior. The resulting S-protected thiomer (TGA-MNA) exhibited 840 mu mol of covalently linked 6-MNA per gram thiomer. Based on the implementation of this hydrophobic ligand on the thiolated backbone, the disintegration behavior was reduced greatly and a controlled release of the peptide could be achieved. Furthermore, permeation studies with TGA-MNA on rat intestine revealed a 4.5-fold enhanced absorptive transport of the peptide in comparison to antide in solution. Additional in vivo studies confirmed the potential of this novel conjugate. Oral administration of antide in solution led to only very small detectable quantities in plasma with an absolute and relative bioavailability (BA) of 0.003 and 0.03%, only. In contrast, with antide incorporated in TGA-MNA matrix tablets an absolute and relative BA of 1.4 and 10.9% could be reached, resulting in a 421-fold increased area under the plasma concentration time curve (AUC) compared to the antide solution. According to these results, S-protected thiolated chitosan as oral drug delivery system might be a valuable tool for improving the bioavailability of peptides. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:477 / 485
页数:9
相关论文
共 30 条
[1]  
Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO
[2]  
2-J
[3]   Regulation of PTP1B via glutathionylation of the active site cysteine 215 [J].
Barrett, WC ;
DeGnore, JP ;
König, S ;
Fales, HM ;
Keng, YF ;
Zhang, ZY ;
Yim, MB ;
Chock, PB .
BIOCHEMISTRY, 1999, 38 (20) :6699-6705
[4]   The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins [J].
Bernkop-Schnurch, A .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (1-2) :1-16
[5]   The use of thiolated polymers as carrier matrix in oral peptide delivery -: Proof of concept [J].
Bernkop-Schnürch, A ;
Pinter, Y ;
Guggi, D ;
Kahlbacher, H ;
Schöffmann, G ;
Schuh, M ;
Schmerold, I ;
Del Curto, MD ;
D'Antonio, M ;
Esposito, P ;
Huck, C .
JOURNAL OF CONTROLLED RELEASE, 2005, 106 (1-2) :26-33
[6]   Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates [J].
Bernkop-Schnurch, A ;
Krajicek, ME .
JOURNAL OF CONTROLLED RELEASE, 1998, 50 (1-3) :215-223
[7]   Synthesis and characterisation of mucoadhesive thiolated polymers [J].
Bernkop-Schnürch, A ;
Steininger, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 194 (02) :239-247
[8]   Chemically modified chitosans as enzyme inhibitors [J].
Bernkop-Schnürch, A ;
Kast, CE .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 52 (02) :127-137
[9]  
Bernkop-Schnürch A, 2001, CRIT REV THER DRUG, V18, P459
[10]   PROTEIN THIOLATION AND REVERSIBLE PROTEIN-PROTEIN CONJUGATION - N-SUCCINIMIDYL 3-(2-PYRIDYLDITHIO)PROPIONATE, A NEW HETEROBIFUNCTIONAL REAGENT [J].
CARLSSON, J ;
DREVIN, H ;
AXEN, R .
BIOCHEMICAL JOURNAL, 1978, 173 (03) :723-737